WPC 9(x99*p3T?+}*9`V%„.L×rzDl6 /[ Ie6`ֱQy%`ZiWGn_Î:GU!Zsu/󔪢,3܀y'jG ~> }õJ1f6@&|)т͑>ؘp&s,u9~M[:*L i}$i֏W늿fDѥ=㵿Lj郙ovrt)]>dB1~,z8\oK_ vJ tRg0r}\,⧢:%l{CP?p܏MQArQOGI~zjk%F=v34-_?=8+RI^Həkɖ!1N;gLԵJ`T'ېi#UN_ % 0:UN 1u; 72^ w4 m 0oc.hp LaserJet 1300 PCL 5e,,,,0(9 Z6Times New Roman RegularX($USUS.,(9 Z 6Times New Roman Regular3#37=CIQYag1.a.i.(1)(a)(i)1)a)i)wsH2 a1:i+003|xU(;3$2#  0  .3  0  !USUS.,  _ XXXX  Unit_12:_ԀObjectives:0 @ AdverseEffectsofBloodTransfusion #XXXXx#  XXXX"3"  3r2#  1  .3  0 (   Contrastimmediateadverseeffectswithdelayedadverseeffectsoftransfusion.3r݌(%(% Ќ  "3"  32#  2  .3  0 (   Listthesignsandsymptomswhichshouldbelookedforbythetransfusionistwhichmaybe  indicativeofahemolytictransfusionreaction.0(%(%3݌%% Ќ  "3"  32#  3  .3  0 (   Statethefiveactionswhichmustbeperformedbythetransfusionistwheneveradverseeffectsof l transfusionoccur.31݌X(%(% Ќ  "3"  3T2#  4  .3  0 (   Statethethreeactionswhichcomprisethelaboratoriesevaluationofthesuspected3T݌D t(%(% Ќ  0 ( hemolytictransfusionreaction(HTR).0 `(%(% "3"  32#  5  .3  0 (   Describethestepsandtestingwhichmustbeperformedwhenclinicaleventssuggestthe0H!(%(%0#H!%H!%0@#p(#p(#3݌ L #%#% Ќ  0 ( possibilityofanHTR. 8 (%(% "3"  3]2#  6  .3  0 (   Describethetestswhichmustbeperformedonthepretransfusionandposttransfusionsampleswhen  $  theDATispositiveand/orhemolysisispresentintheimmediateposttransfusionspecimen.3]݌  (%(% Ќ  "3"  3 2#  7  .3  0 (   Listsevenpossiblecausesofnonimmunehemolysis.3 % ݌ (%(% Ќ  "3"  3 2#  8  .3  0 (   Describetherecommendedtestingtoperformtomonitorthepatient'sclinicalconditionwhen   hemolysishasbeenproven.3 ݌ (%(% Ќ  "3"  3G 2#  9  .3  0 (   Listsevenadditionaltestswhichmaybeperformedwhenroutinetestsareuninformativeandimmune  hemolysisisstillstronglysuspected.3G t ݌|(%(% Ќ  "3 "  3 2#  10  .3  0 (   Statethemostcommoncauseoflifethreateninghemolytictransfusionreactions.3 ݌h(%(% Ќ  "3 "  32#  11  .3  0 (   DescribetheclinicalsignsandsymptomsoftenobservedduringanacuteHTR.3݌T(%(% Ќ  "3 "  32#  12  .3  0 (   Describethegoaloftreatmentoftheacutehemolytictransfusionreaction.3 ݌@p(%(% Ќ  "3 "  32#  13  .3  0 (   Explainwhytotalpreventionofhemolytictransfusionreactionsisimpossible.3݌,\(%(% Ќ  "3 "  3 2#  14  .3  0 (   Define"febrilenonhemolyticreactions"andtheproductofchoiceforthesepatients.0H!(%(%0#H!%H!%0@#p(#p(#3 7݌H#%#% Ќ  "3"  3f2#  15  .3  0 (   Describethesymptomswhichmayoccur,theappearanceoftheunitandlaboratoryinvestigation 4 whenbacterialcontaminationissuspected.3f݌ (%(% Ќ  "3"  32#  16  .3  0 (   Describethefeatureswhichdistinguishananaphylacticreactionfromotherimmediate3݌ (%(% Ќ  0 ( adversereactions.(%(% "3"  3)2#  17  .3  0 (   Statetheconstituentofplasmawhichmayberesponsibleforanaphylacticreactionsandtheproducts  ofchoicefortransfusingtheseindividuals.3)V݌(%(% Ќ  "3"  32#  18  .3  0 (   Describethecutaneoushypersensitivityreaction,includingthemostlikelycauseandtreatment.3݌(%(% Ќ  "3"  32#  19  .3  0 (   Statetheonlyimmediateadverseeffectinwhichthetransfusionmaycontinue.3݌x(%(% Ќ  "3"  32#  20  .3  0 (   Describethesignsandsymptomsassociatedwithcirculatoryoverload.3݌d(%(% Ќ  "3"  32#  21  .3  0 (   Statetherecommendedtransfusionprotocoltofollowwhenpatientsaresusceptibletocirculatory P   overload.3݌